Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.
Calleja
E M
EM
Division of Pediatric Hematology, New York Hospital/Cornell University Medical College, New York 10021, USA.
Shen
J Y
JY
Lesser
M
M
Grady
R W
RW
New
M I
MI
Giardina
P J
PJ
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000453:epidemiology; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007037:Hypothyroidism / Q000453:epidemiology; D015994:Incidence; D007263:Infusions, Parenteral; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009017:Morbidity; D011627:Puberty; D015996:Survival Rate; D013997:Time Factors; D017086:beta-Thalassemia / Q000150:complications / Q000401:mortality / Q000628:therapy*
D007502:Iron Chelating Agents; D005293:Ferritins; D003676:Deferoxamine